Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart

Exclusion Criteria

• •type I diabetes mellitus
• •current treatment with insulin
• •pregnant and breast-feeding women
• •any medication known to influence insulin sensitivity
• •current treatment with systemic corticosteroids
• •history of acute metabolic complications in the past 3 months
• •recurrent severe hypoglycaemia or hypoglycaemic unawareness
• •active proliferative diabetic retinopathy and known diabetic gastroparesis
• •impaired hepatic function, as shown but not limited to ALT or AST above 2 times the upper limit of normal
• •clinically relevant illness such as nephropathy and impaired renal function as shown by clearance \< 30 ml/min
• •any history or presence of clinically relevant abnormality, medical condition (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, ocular or infectious disease; any acute infectious disease or signs of acute illness making implementation of the protocol or interpretation of the results difficult
• •hypersensitivity to insulins or insulin analogs
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.